PDCD1 and neoplasm: This ubiquitination leads to PD-1 degradation, enhancing cytotoxic lymphocyte infiltration into the tumor microenvironment and impairing the sensitivity of non-small cell lung cancer (NSCLC) to anti-PD-1 immunotherapy.